1259372-69-4

VU0155041 is a positive allosteric modulator of metabotropic glutamate receptor 4 (mGluR4) with an EC₅₀ value of 2.5 μM for glutamate response in a thallium flux assay. It is selective for mGluR4, exhibiting no effect on radioligand binding at 67 G protein-coupled receptors, ion channels, and transporters, and lacking antagonist activity at NMDA receptors in striatal medium spiny neurons at a concentration of 10 μM. In vivo, VU0155041 decreases catalepsy induced by haloperidol and reverses askinesias induced by reserpine in rat models of Parkinson’s disease. Chronic treatment with VU0155041 restores social behavior in the Oprm^-/- mouse model of autism. It also increases the percentage of time spent in the open arms of the elevated plus maze, a measure of decreased anxiety, in mice.

VU 0155041 Sodium Salt is a positive allosteric modulator of group III mGlu4 receptor that provides functional neuprotection in 6-hydroxydopamine rat models with parkinson’s disease.

mGluR4: 693 nM (EC₅₀)

Desiccate at RT

[1] COLLEEN M NISWENDER. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4.[J]. Molecular Pharmacology, 2008, 74 5: 1345-1358. DOI: 10.1124/mol.108.049551
[2] JéR?ME AJ BECKER. Autistic-Like Syndrome in Mu Opioid Receptor Null Mice is Relieved by Facilitated mGluR4 Activity[J]. Neuropsychopharmacology, 2014, 39 9: 2049-2060. DOI: 10.1038/npp.2014.59
[3] ROBERT M. DUVOISIN . Opposing roles of mGluR8 in measures of anxiety involving non-social and social challenges[J]. Behavioural Brain Research, 2011, 221 1: Pages 50-54. DOI: 10.1016/j.bbr.2011.02.049